151 related articles for article (PubMed ID: 30772655)
1. Mitochondrial myopathy associated with anti-programmed cell death 1 therapy.
Ibrahim T; Adam C; Routier E; Slama A; Robert C
Eur J Cancer; 2019 Mar; 110():71-73. PubMed ID: 30772655
[No Abstract] [Full Text] [Related]
2. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
[No Abstract] [Full Text] [Related]
3. Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab.
Tadokoro T; Keshino E; Makiyama A; Sasaguri T; Ohshima K; Katano H; Mohri M
Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27650418
[No Abstract] [Full Text] [Related]
4. Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
Thomas M; Armenti ST; Ayres MB; Demirci H
JAMA Ophthalmol; 2018 May; 136(5):553-556. PubMed ID: 29677240
[TBL] [Abstract][Full Text] [Related]
5. Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy.
Hoadley A; Sandanayake N; Long GV
Ann Oncol; 2017 Feb; 28(2):434-435. PubMed ID: 27864215
[No Abstract] [Full Text] [Related]
6. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R
Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803
[No Abstract] [Full Text] [Related]
7. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
[No Abstract] [Full Text] [Related]
8. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
[TBL] [Abstract][Full Text] [Related]
9. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
Amini-Adle M; Balme B; Dalle S
Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
[No Abstract] [Full Text] [Related]
10. PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis.
So H; Ikeguchi R; Kobayashi M; Suzuki M; Shimizu Y; Kitagawa K
J Neurol Sci; 2019 Apr; 399():97-100. PubMed ID: 30798111
[No Abstract] [Full Text] [Related]
11. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
Amode R; Baroudjian B; Kowal A; Jebali M; Allayous C; Bagot M; Madjlessi N; Roux J; Viguier M; Basset Seguin N; Porcher R; Pagès C; Lebbé C
Melanoma Res; 2017 Apr; 27(2):110-115. PubMed ID: 27926587
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
Fiset PO; Shapera S; Butler MO; Tsao MS
Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
[No Abstract] [Full Text] [Related]
13. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
15. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
16. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
17. Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.
Deltombe C; Garandeau C; Renaudin K; Hourmant M
Transplantation; 2017 Sep; 101(9):e291. PubMed ID: 29633980
[No Abstract] [Full Text] [Related]
18. Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab.
Watanabe Y; Yamaguchi Y; Takamura N; Takahashi Y; Aihara M
Eur J Cancer; 2020 May; 131():1-4. PubMed ID: 32248069
[No Abstract] [Full Text] [Related]
19. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series.
Tomelleri A; Campochiaro C; De Luca G; Cavalli G; Dagna L
Eur J Intern Med; 2018 Nov; 57():e11-e12. PubMed ID: 30076088
[No Abstract] [Full Text] [Related]
20. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
Johansen A; Christensen SJ; Scheie D; Højgaard JLS; Kondziella D
Neurology; 2019 Apr; 92(14):663-674. PubMed ID: 30850443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
